GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel

Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.

Zacks Investment Research • 6 hours ago

Gilead to acquire Arcellx for $7.8 billion

Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.

Reuters • Feb 23, 2026

Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with an equity value of $7.8 billion.

Market Watch • Feb 23, 2026

Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J

Gilead will pay an extra $5 a share if anito-cel sales hit $6 billion by 2029.

Investors Business Daily • Feb 23, 2026

Gilead pays $7.8bn to take full control of promising multiple myeloma therapy

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this year. The offer of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of 20 February.

Proactive Investors • Feb 23, 2026

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

Gilead Sciences will pay as much as $7.8 billion to acquire its partner Arcellex in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer treatments.

Reuters • Feb 23, 2026

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't a mystery rally.

Invezz • Feb 23, 2026

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time The live webcasts can be accessed at the company's investors pa.

Business Wire • Feb 23, 2026

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.

Gilead Sciences is paying an 80% premium to Friday's closing price.

Barrons • Feb 23, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.

Business Wire • Feb 23, 2026